Astrana Health, Inc. (NASDAQ:ASTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $56.83.

A number of brokerages have commented on ASTH. Stifel Nicolaus decreased their target price on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Robert W. Baird decreased their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Bank of America decreased their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Finally, Truist Financial cut their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 13th.

Institutional Investors Weigh In On Astrana Health

Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC bought a new stake in Astrana Health during the third quarter worth approximately $35,000. Pilgrim Partners Asia Pte Ltd bought a new stake in Astrana Health during the fourth quarter worth approximately $40,000. Quarry LP raised its holdings in Astrana Health by 35.5% during the fourth quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after purchasing an additional 471 shares in the last quarter. KBC Group NV bought a new stake in Astrana Health during the third quarter worth approximately $70,000. Finally, Quest Partners LLC bought a new stake in Astrana Health during the third quarter worth approximately $133,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Up 8.0 %

NASDAQ:ASTH opened at $29.38 on Friday. The company has a market capitalization of $1.65 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. Astrana Health has a one year low of $23.12 and a one year high of $63.20. The stock has a 50-day simple moving average of $34.25 and a 200 day simple moving average of $43.80. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Sell-side analysts predict that Astrana Health will post 1.15 EPS for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.